c-mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia
about
The molecular mechanisms that control thrombopoiesisMegakaryocyte biology and related disordersClinical indications for thrombopoietin and thrombopoietin-receptor agonistsExome sequencing identifies MPL as a causative gene in familial aplastic anemiaThe thrombopoietin receptor, c-Mpl, is a selective surface marker for human hematopoietic stem cells.Lnk controls mouse hematopoietic stem cell self-renewal and quiescence through direct interactions with JAK2MERIT40 deficiency expands hematopoietic stem cell pools by regulating thrombopoietin receptor signalingThe genomics of inherited bone marrow failure: from mechanism to the clinic.Incomplete restoration of Mpl expression in the mpl-/- mouse produces partial correction of the stem cell-repopulating defect and paradoxical thrombocytosis.Polycomb repressive complex 2 (PRC2) restricts hematopoietic stem cell activityAutoantibody to c-Mpl (thrombopoietin receptor) in systemic lupus erythematosus: relationship to thrombocytopenia with megakaryocytic hypoplasia.Thrombopoietin is essential for the maintenance of normal hematopoiesis in humans: development of aplastic anemia in patients with congenital amegakaryocytic thrombocytopenia.Allogeneic stem cell transplantation for patients with congenital amegakaryocytic thrombocytopenia (CAT).A neonate with severe thrombocytopenia and radio-ulnar synostosis.Thrombopoietin regulates differentiation of rhesus monkey embryonic stem cells to hematopoietic cells.Qualitative disorders of platelets and megakaryocytes.The molecular basis of congenital thrombocytopenias: insights into megakaryopoiesis.Congenital amegakaryocytic thrombocytopenia: a retrospective clinical analysis of 20 patients.Current diagnosis of inherited bone marrow failure syndromes.Characterization of a patient with atypical amegakaryocytic thrombocytopenia.Historical review: megakaryopoiesis and thrombopoiesisJAK and MPL mutations in myeloid malignancies.Functional analysis of single amino-acid mutations in the thrombopoietin-receptor Mpl underlying congenital amegakaryocytic thrombocytopenia.An ENU-induced recessive mutation in Mpl leads to thrombocytopenia with overdominanceMutational inhibition of c-Myb or p300 ameliorates treatment-induced thrombocytopeniaCompound heterozygous c-Mpl mutations in a child with congenital amegakaryocytic thrombocytopenia: functional characterization and a review of the literatureCongenital amegakaryocytic thrombocytopenia and thrombocytopenia with absent radii.Gene therapy of MPL deficiency: challenging balance between leukemia and pancytopenia.Thrombopoietin and platelet production in chronic immune thrombocytopenia.Inherited platelet disorders: thrombocytopenias and thrombocytopathies.F104S c-Mpl responds to a transmembrane domain-binding thrombopoietin receptor agonist: proof of concept that selected receptor mutations in congenital amegakaryocytic thrombocytopenia can be stimulated with alternative thrombopoietic agents.MegakaryopoiesisCurrent status of thrombopoietic agents.Congenital amegakaryocytic thrombocytopenia: a brief review of the literatureCAMT in a female with developmental delay, facial malformations and central nervous system anomalies.Platelet disorders in children: A diagnostic approach.Congenital amegakaryocytic thrombocytopenia.Thrombopoietin and hematopoietic stem cells.Inherited platelet disorders: a clinical approach to diagnosis and management.Nonclinical safety assessment of a synthetic peptide thrombopoietin agonist: effects on platelets, bone homeostasis, and immunogenicity and the implications for clinical safety monitoring of adverse bone effects.
P2860
Q24536138-E60B739C-EAA0-4D96-AF4F-17B3E7CA909FQ24536140-06691131-FE86-482B-A3AE-059D1C7279B8Q24601161-1116FC3B-B40E-47AD-95A6-716E55B68343Q24626423-AEE739C4-61D7-45A0-9131-555DDA6D6D0DQ25257167-DDD7C632-D3C0-4A9D-8730-93C351BE34E5Q28508573-52D13A67-0889-49B5-92CB-3FA95043550FQ28854388-1B82D2B6-77E9-48B5-AB47-2E0171706F8AQ30235895-45CB14F6-B527-41FF-BD46-63FF82EFEC51Q30486155-F833EBBD-BD06-4221-A4FA-5FA79AFEA0FAQ33328634-D5C7786F-FEEC-4E95-961C-AFF80C091AA6Q33344045-C8D6CBD0-F4BA-4173-AA73-7721A0FDDDB0Q33348440-76795007-530B-451C-BE1E-867D9F667953Q33359598-1E4E07EB-69E1-4577-B602-C64C27973566Q33361877-22E40977-8E81-4E5B-BD3C-B75527D4F473Q33366796-6310547D-C0B8-497A-B55C-50E5AEE4EBB7Q33367864-F05986F7-8013-4D0B-883C-EAFF6F476135Q33368674-FA700DE2-25EF-47E1-805F-B94C8799F91BQ33369564-115C1F97-3BD5-4423-A603-F28ED06FE144Q33374981-63299C99-35E6-47B4-8A32-78F0AFA3BC25Q33378274-28C83D39-7D35-4732-BC04-87642977B533Q33378422-7E5357E5-91CA-4B58-A9FE-CA15AEEAF25AQ33378737-2B63B5C0-62AA-4DF3-BC78-9435DE5709A9Q33379321-BC751FFC-82A2-4CB5-9D63-F19ECF48B602Q33382312-17C9FD0B-62DC-44BD-8F4C-A4FAF6C522DCQ33383503-A0D2EF78-1BE6-416A-ACD3-8956CEA26D7CQ33383806-AB7A492F-ED73-400F-B907-B95B8B3995ABQ33383921-0BE60CA9-2BC0-4C2F-A9D4-0E69BB8592C7Q33386724-6E53793A-483B-4174-8088-A9F1ED8EEDB3Q33387153-60408B12-B8A7-47BD-B8AB-9E51345CD1FAQ33387543-CF149BA3-AFDE-4787-BFEE-535902047C67Q33388407-A69591D6-9ECC-43B6-B87D-AEC716A1A11EQ33390616-26DCD80E-B90F-487B-9863-6442BD556ABAQ33392858-C22ADF6C-CB76-4D8C-933E-3C540284DC99Q33393255-FB3B0A5E-CB4F-4EA0-863F-D5451E404CA2Q33393619-83EF09B1-DC25-4F19-A982-C7C04B544D71Q33393990-27455416-D841-415F-AA77-9EB6251CDA0BQ33394248-700AFFBA-CF23-4FB9-BD81-6CB658CF3FBCQ33394846-7A7C136D-64E3-48EE-AC08-C1330680504FQ33396427-0DC36356-A28B-4945-B55F-2249BA7FE6D0Q33396650-415CEBA8-7D74-471F-9D28-5CA7FCAAC75F
P2860
c-mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
c-mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia
@ast
c-mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia
@en
c-mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia
@nl
type
label
c-mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia
@ast
c-mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia
@en
c-mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia
@nl
prefLabel
c-mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia
@ast
c-mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia
@en
c-mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia
@nl
P2093
P921
P3181
P356
P1433
P1476
c-mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia
@en
P2093
K Cherkaoui
M Ballmaier
M Germeshausen
S Krukemeier
P304
P3181
P356
10.1182/BLOOD.V97.1.139
P407
P577
2001-01-01T00:00:00Z